Bioregulator Stack
AKA Khavinson stack · Longevity bioregulators
Last reviewed 2026-10-30
Our read Opinion
Niche but growing with the longevity crowd.
Claims made by sellers, clinics and users. Not verified.
Slowing biological aging: telomeres, sleep/circadian rhythm and brain aging.
Both come from the Russian 'peptide bioregulator' research school, which claims short peptides regulate gene expression in specific organs; Epitalon targets the pineal gland, Pinealon the brain.
Evidence level: Animal studies mostly
No published human trials of this combination. Evidence comes almost entirely from one research group.
No human trials have tested this combination. Combining compounds can also combine unknown side effects and interactions.
Epitalon is compoundable alone under the HHS policy; Pinealon is not covered.
Statuses change; check the linked primary sources.
Fascinating claims that independent labs have not replicated.
| Field | Epitalon | Pinealon |
|---|---|---|
| Type | Research Only | Research Only |
| Regulatory status | No FDA approval; foreign authorization unverified | No FDA approval; foreign authorization unverified |
| Compounding status | Off Category 2, review pending | Unclear / not listed |
| FDA-approved indications | None | None |
| Categories | Longevity & mitochondrial | Longevity & mitochondrial, Cognitive & mood |
| Claimed uses |
|
|
| Mechanism | A synthetic tetrapeptide investigated for effects on telomerase, cellular aging and pineal melatonin regulation. These mechanistic observations do not establish human lifespan extension. | A Glu-Asp-Arg tripeptide studied for neuronal resistance to hypoxic and oxidative stress. Proposed effects include modulation of antioxidant defenses and excitotoxicity. |
| Evidence level | Small/early human studies | Animal studies mostly |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Watch | Watch |
| Routes | Injection | — |
| WADA | Verify | Verify |
| Where it stands (opinion) | Limited human melatonin reports accompany mostly preclinical longevity research. FDA retains safety concerns after nomination withdrawal; robust human longevity evidence is absent. | Published evidence is mainly experimental hypoxia and cell research. Established clinical benefit, long-term safety and a US compounding clearance were not verified. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 1 | 0 |
STAT
Reporters examine claims made by clinics promoting epitalon for aging.
Information only. Not medical advice. Describing a stack is not a recommendation to combine, obtain or use any compound. Ratings and "Our Take" are editorial opinion. Full disclaimer.